Avycaz
(Ceftazidime)ApprovedSmall molecule
This medication is a combination antibiotic used to treat serious bacterial infections including abdominal infections, hospital-acquired pneumonia, and kidney or urinary tract infections. It contains ceftazidime, which kills bacteria, plus avibactam, which prevents bacteria from resisting the antibiotic's effects.[2] Avycaz is currently approved and in use across 23 indications[4].[1]
Avycaz is one of 312 small molecule programs targeting Osteomyelitis. It is currently in Approved.
23
Indications
23
Total Trials
2
Active Trials
311
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 23 indications
Competition
Competitive Landscape
155 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Avycaz
PPhiladelphia Eye Associates
Approved
Jakafi
IncytePreclinical
Primaquine
SanofiPreclinical
Acanya
PfizerPreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Advil
KKenvue Brands
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cystic Fibrosis4 trials
Show 1 more trial
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Terminated·AAssociation Nationale pour les Traitements A Domicile, les Innovations et la Recherche·Phase 4·NCT00333385·120 enrolled
Peritonitis2 trials
Hematologic Malignancies1 trial
Neutropenia1 trial
Double-blind1 trial
14 more indications
Antibiotics1 trial
Complication1 trial
Dialysis Patients1 trial
Randomized1 trial
Urinary Tract Infection1 trial
Ventilator-Associated Pneumonia1 trial
Infection in ICU1 trial
Early Optimization of Ceftazidime Regimen in Critical Care
Not yet recruiting·CCentre Hospitalier Universitaire de Saint Etienne·Preclinical·NCT07085624·128 enrolled
Regulatory
FDA Approval Timeline[5]
Jul 19, 1985
FORTAZ
NDA NDA050578
Apr 28, 1989
FORTAZ IN PLASTIC CONTAINER
NDA NDA050634
Sep 27, 1990
CEPTAZ
NDA NDA050646
Jun 13, 2011
CEFTAZIDIME IN DEXTROSE CONTAINER
NDA NDA050823
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Avycaz drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ceftazidime. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Bacterial Penicillin-Binding Protein Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- PPhiladelphia Eye Associates